The core laboratory at Hsinchu Biomedical Science Park under the guidance of TIRI has comprehensively planned and established R&D facilities as well as service platforms conformed to international medical device regulations. Through integrating industries, academia, and corporate institutions, it can effectively decrease the certification time and costs of 3D-printed medical device prototypes. It also assists industries in obtaining accelerated US FDA approval. Hence, it can facilitate Taiwan’s domestic biotechnology industry innovation and benefit economics.